The FDA has paused new public releases of complete response letters (CRLs) as the agency seeks to strengthen its legal basis for disclosing sensitive rejection information. The move comes as FDA develops a framework intended to reduce litigation exposure while clarifying how and when CRLs can be released. The announcement reflects the tension between transparency initiatives and the legal risk surrounding publication of detailed, often competition-sensitive details tied to unapproved drugs. For biotech sponsors, the pause may slow visibility into regulatory outcomes during development cycles, even as the FDA’s stated intent is to create a more stable disclosure approach moving forward.